title: Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma.
abstract: The platinum-based chemotherapeutic agents, such as cisplatin (CDDP) and carboplatin (CBDCA), are effective for small cell lung carcinoma (SCLC). However, high dose treatment of these agents required for advanced-stage SCLC is often associated with severe toxicity. The authors used combination of lower doses of both cisplatin and carboplatin combined with etoposide (VP-16) to minimize side effects of these agents. This goal was accomplished by utilizing the facts that each agent has its own toxicity that can be controlled individually. Two patients (60- and 71-year old men) with multiple metastatic brain tumors from SCLC were treated by our chemotherapeutic regimen. After fourth chemotherapy, remarkable shrinking of brain masses was associated with significant decrease the size of original lung lesions in both cases. The two patients were discharged without any side effects of the treatment, and neurological deficits subsided in both cases. Each course provided the following schedules: carboplatin 200 mg/m2 x 1 day, cisplatin 25 mg/m2 x 2 days (intravenous administration), and etoposide 25 mg oral x 14 days. After second chemotherapy, the patient of Case 1 was irradiated to both brain and chest lesions, and only to brain in Case 2. The authors concluded from our two cases that the combination of these agents extremely effective to treat this malignancy with less toxicity. We named this double platinum chemotherapy as 'PEC', abbreviated from cisplatin, etoposide, and carboplatin. m
authors.affiliation: Department of Neurosurgery, Mizonokuchi Hospital, Teikyo University, Japan. yamadasm@med.kochi-u.ac.jp
authors.forename: Shoko M
authors.initials: SM
authors.lastname: Yamada
authors.forename: Shokei
authors.initials: S
authors.lastname: Yamada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Akira
authors.initials: A
authors.lastname: Teramoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakayama
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D024221:Antineoplastic Protocols; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin
references.citation: Am J Clin Oncol. 1997 Oct;20(5):500-4
references.pmid: 9345336
references.citation: Am J Clin Oncol. 1997 Apr;20(2):125-7
references.pmid: 9124183
references.citation: J Clin Oncol. 2001 Aug 1;19(15):3532-8
references.pmid: 11481360
references.citation: Med Oncol. 1998 Apr;15(1):66-9
references.pmid: 9643534
references.citation: Semin Oncol. 2001 Jun;28(3 Suppl 10):15-8
references.pmid: 11510029
references.citation: Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527-31
references.pmid: 387223
references.citation: Cancer Metastasis Rev. 2001;20(1-2):13-25
references.pmid: 11831641
references.citation: J Clin Oncol. 1987 Feb;5(2):185-9
references.pmid: 3027268
references.citation: J Chemother. 1995 Oct;7(5):460-2
references.pmid: 8596133
references.citation: J Clin Oncol. 1989 Jul;7(7):916-22
references.pmid: 2544685
references.citation: N Engl J Med. 1999 Aug 12;341(7):476-84
references.pmid: 10441603
references.citation: Acta Radiol Oncol. 1985 Nov-Dec;24(6):475-9
references.pmid: 3006436
references.citation: J Clin Oncol. 1989 May;7(5):651-61
references.pmid: 2651580
references.citation: J Clin Oncol. 1985 Nov;3(11):1471-7
references.pmid: 2997406
references.citation: J Clin Oncol. 1994 Nov;12(11):2327-32
references.pmid: 7964948
references.citation: J Clin Oncol. 1994 Oct;12(10):2022-34
references.pmid: 7931470
references.citation: Respir Med. 2001 Mar;95(3):235-6
references.pmid: 11266242
references.citation: Am J Clin Oncol. 1996 Apr;19(2):193-8
references.pmid: 8610649
references.citation: Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7
references.pmid: 11164720
references.citation: J Natl Cancer Inst. 1995 Feb 1;87(3):183-90
references.pmid: 7707405